IP Library Granted Patent US 11,583,581
Granted Patent B2
US 11,583,581 · App. 15/760,424 · Granted Feb 21, 2023

Methods of treating a retroviral infection

Inventors: Matthias Schroff (Berlin, DE); Manuel Schmidt (Berlin, DE); Kerstin Kapp (Berlin, DE); Alfredo Zurlo (Berlin, DE); Ole Schmeltz Sogaard (Berlin, DE); Martin Tolstrup (Berlin, DE); Rasmus Offersen (Berlin, DE)
Assignee: Gilead Sciences, Inc.
A61K39/39A61K31/711C12N15/117C12N15/1132A61K2039/55561C12N2310/17C12N2320/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,583,581
App. No.
15/760,424
Granted
Feb 21, 2023
Kind
B2
Abstract

The invention relates to a non-coding sequence of deoxyribonucleic acids comprising at least one sequence motif N 1 N 2 CGN 3 N 4 , wherein N is a nucleotide comprising A, C, T, or G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxy-thymidine for the treatment of viral infections. In particular, the non-coding sequence of deoxyribonucleic acids is used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors.

Claims (12)

1. A method of treating a latent human immunodeficiency virus 1 (HIV-1) infection in a patient in need thereof, comprising administering to the patient a non-coding sequence of deoxyribonucleic acids comprising

(SEQ ID NO: 5)

CCTAGGGGTT ACCACCTTCA TTGGAAAACG TTCTTCGGGG

CGTTCTTAGG TGGTAACC CCTAGGGGTT ACCACCTTCA

TTGGAAAACG TTCTTCGGGG CGTTCTTAGG TGGTAACC

in combination with combination antiretroviral therapy.

2. The method of claim 1 , wherein the non-coding sequence of deoxyribonucleic acids has a length of up to 200 nucleotides.

3. The method of claim 1 , wherein the non-coding sequence of deoxyribonucleic acids has a length of 116 nucleotides.

4. The method of claim 1 , where the non-coding sequence of deoxyribonucleic acids is part of a single stranded region.

5. The method of claim 1 comprising administering the non-coding sequence of deoxyribonucleic acids simultaneously, alternating or successively with combination antiretroviral therapy.

6. The method of claim 5 , wherein the non-coding sequence of deoxyribonucleic acids is administered prior to combination antiretroviral therapy.

7. The method of claim 1 , wherein the non-coding sequence of deoxyribonucleic acids is administered as an adjuvant in therapeutic or prophylactic vaccination.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2020
From: MOLOGEN AG
To: GILEAD SCIENCES, INC.
Reel/Frame 054858/0419 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2018
From: SCHROFF, MATTHIAS; SCHMIDT, MANUEL; KAPP, KERSTIN; ZURLO, ALFREDO; SOGAARD, OLE SCHMELTZ; TOLSTRUP, MARTIN; OFFERSEN, RASMUS
To: MOLOGEN AG
Reel/Frame 048413/0258 →
Priority Claims (1)
GB 1516676 · Sep 21, 2015 · national
Continuity (1)
Related Publication 20200230234A1 · Jul 23, 2020